– CE-markering-compatibele software; binnenkort beschikbaar in Europa –

TOKIO–(BUSINESS WIRE)– NEC Corporation (NEC; TOKYO: 6701) heeft vandaag de ontwikkeling aangekondigd van een AI-technologie om artsen te ondersteunen bij het bepalen of colorectale laesies neoplastisch of niet-neoplastisch zijn. NEC ontwikkelde een nieuwe technologie, “Cx20” genaamd, terwijl het probeerde te helpen bij de vroege detectie van colorectale laesies. Cx20 heeft al voldaan aan de vereisten voor CE-markering, een Europese norm voor veiligheid, gezondheid en milieubescherming, en zal worden geïntegreerd in de diagnostische ondersteuningssoftware voor medische apparaten AI “WISE VISION® Endoscopie” (*1), waarvan de verkoop naar verwachting in Europa zal beginnen later dit jaar.

Deze software maakt verbinding met en werkt samen met bestaande endoscopische apparatuur en stelt gebruikers automatisch op de hoogte als een laesie mogelijk neoplastisch is op basis van beelden die zijn vastgelegd tijdens endoscopieprocedures. De software wordt dan direct een extra hulpmiddel om endoscopisten te helpen bij het differentiëren van laesies en het ontlasten van patiënten.

NEC’s Artificial Intelligence (AI) Supports Doctors to Determine If Colorectal Lesions Are Potentially Neoplastic

– CE marking-compliant software; soon available in Europe –

TOKYO–(BUSINESS WIRE)– NEC Corporation (NEC; TOKYO: 6701) announced today the development of an AI technology for supporting doctors in determining if colorectal lesions are neoplastic or non-neoplastic. NEC developed a new technology, called “Cx20,” while seeking to assist in the early detection of colorectal lesions. Cx20 has already met the requirements for CE marking, a European safety, health and environmental protection standard, and will be integrated in the medical device AI diagnostic support software “WISE VISION® Endoscopy” (*1), with sales expected to start in Europe later this year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210714005377/en/

The Cx20 function supports the identification of disease: During examinations, suspected lesions are automatically detected through video taken by endoscope devices. Doctors then extract still images (left) and analysis results are soon displayed (right) (Graphic: Business Wire)

This software connects and interacts with existing endoscopic equipment and automatically notifies users if a lesion is possibly neoplastic based on images captured during endoscopy procedures. The software then becomes an extra tool immediately available to assist endoscopists in the differentiation of lesions and reduces the burden on patients.

Colorectal cancer originates from precancerous lesions (colorectal neoplastic polyps) and it is possible to suppress its progression by detecting and removing lesions at an early stage during endoscopy procedures. It is, however, sometimes difficult for endoscopists to visually distinguish between neoplastic and non-neoplastic lesions during endoscopy examinations, resulting in unnecessary biopsies and removal of non-neoplastic lesions, thereby causing additional stress and discomfort to patients. Colorectal cancer is said to be the second-largest cancer (*2) in the European region, and the latest version of WISE VISION® Endoscopy, which launches first in Europe, promises to help doctors address this challenging issue.

To improve the chances of identifying if colorectal lesions are possibly neoplastic, and so to help endoscopists in their decision process, NEC developed a new technology where the learning power of AI is used to combine information of endoscopy images and data from the findings of expert physicians. Specifically, the technology analyzes still images of lesions taken with endoscopy devices, and if the AI determines that a colorectal lesion is likely to be neoplastic a “High possibility” notification message is displayed.

For More Information

URL: https://www.nec.com/en/press/202107/global_20210714_03.html

——

Notes:

(*1) “WISE VISION” is a registered trademark of NEC Corporation in the United States of America, the European Union and the United Kingdom.

(*2) According to United European Gastroenterology

https://ueg.eu/p/78#

View source version on businesswire.com: https://www.businesswire.com/news/home/20210714005377/en/

Contacts

Joseph Jasper

j-jasper(at)nec.com